Ibio (IBIO) closed at $0.77 on October 27, 2026, up 8.5% from the previous close, on volume of 468,573 shares (30-day average 810,289).
Data as of October 27, 2026.
Globe Newswire (Tue, 13-Oct 7:00 AM ET)
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
Globe Newswire (Tue, 1-Sep 4:30 PM ET)
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Globe Newswire (Fri, 28-Aug 7:00 AM ET)
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Market Chameleon (Wed, 1-Jul 7:09 AM ET)
iBio’s Spotlight at Guggenheim Healthcare Conference Highlights Strategic Push in Obesity Innovation
Market Chameleon (Thu, 23-Oct 6:34 AM ET)
iBio Showcases Promising Activin E Antibody Data Ahead of Obesity and Cardiometabolic Conferences
Market Chameleon (Wed, 22-Oct 7:09 AM ET)
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Ibio trades on the NASDAQ stock market under the symbol IBIO.
As of October 27, 2026, IBIO stock price climbed to $0.77 with 468,573 million shares trading.
IBIO has a beta of 2.78, meaning it tends to be more sensitive to market movements. IBIO has a correlation of 0.10 to the broad based SPY ETF.
IBIO has a market cap of $49.32 million. This is considered a Sub-Micro Cap stock.
Last quarter Ibio reported $0 in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-66,670 and met earnings estimates .
In the last 3 years, IBIO traded as high as $6.89 and as low as $.56.
The top ETF exchange traded funds that IBIO belongs to (by Net Assets): VTI, VXF, IWC.
IBIO has underperformed the market in the last year with a price return of -36.6% while the SPY ETF gained +14.8%. IBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.4% and -15.1%, respectively, while the SPY returned +4.4% and -1.1%, respectively.
IBIO support price is $.66 and resistance is $.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBIO shares will trade within this expected range on the day.
